Filing Analysis
Kwaku Temeng is resigning from the Board of Directors of Core Laboratories Inc., effective October 1, 2026. His resignation is characterized by a disagreement with the Board regarding the company's strategic direction, research priorities, and governance practices related to succession planning.
🚩 Red Flags
- Resignation due to disagreement with the Board of Directors regarding strategic direction.
- Disagreement regarding governance practices and succession planning.
- Disagreement regarding the company's research priorities.
📋 Key Facts
- Kwaku Temeng verbally notified the Board of his intention to resign on August 19, 2026.
- Resignation confirmed via letter on August 25, 2026.
- Effective date of resignation is October 1, 2026.
- Mr. Temeng serves as Chairman of the Nominating Committee and a member of the Compensation Committee.
- Disagreements cited include: strategic direction, research priorities, and succession planning processes.
Core Laboratories Inc. announced its second quarter 2026 financial results and declared a quarterly cash dividend of $0.01 per share.
📋 Key Facts
- Announced Q2 2026 financial results on July 29, 2026.
- Declared a quarterly cash dividend of $0.01 per share of common stock.
- Record date for the dividend is August 10, 2026.
- Payment date for the dividend is August 31, 2026.
Core Laboratories Inc. announced its third quarter 2025 financial results and declared a quarterly cash dividend of $0.01 per share.
📋 Key Facts
- Announced Q3 2025 financial results on October 22, 2025 (Item 2.02).
- Declared a quarterly cash dividend of $0.01 per share of common stock (Item 7.01).
- Record date for the dividend is November 3, 2025.
- Payment date for the dividend is November 24, 2025.
Core Laboratories Inc. entered into a Ninth Amended and Restated Credit Agreement on July 22, 2025, which increases the aggregate borrowing commitment to $150 million and extends the maturity date to July 22, 2029. The amendment also includes specific 'springing maturity' provisions tied to the repayment of existing senior notes.
🚩 Red Flags
- Springing maturity provisions create potential liquidity pressure if senior notes are not fully repaid by their respective dates (Oct 2027/March 2028).
📋 Key Facts
- Aggregate borrowing commitment increased from $135 million to $150 million.
- Includes a $50 million accordion option.
- Revolving credit facility up to $100 million available through maturity date.
- Single draw of $50 million delayed draw term loan available until January 12, 2026.
- Maturity date extended to July 22, 2029.
- Springing maturity clauses: Revolving facility matures early (Oct 2027 or March 2028) if specific portions of 2021 Series B and 2023 Series A Senior Notes remain outstanding.
Core Laboratories Inc. reported the results of its Annual Meeting of Shareholders held on May 21, 2025. All proposed items, including director elections and auditor ratification, were approved by shareholders.
📋 Key Facts
- Annual Meeting held on May 21, 2025, in Houston, Texas.
- Proposal 1: Election of Class II Directors (Martha Z. Carnes, Katherine Murray, and Rob Martinovich) was approved via plurality vote.
- Proposal 2: Ratification of KPMG LLP as the independent registered public accountant for the fiscal year ending December 31, 2025, was approved by an absolute majority.
- Proposal 3: Advisory vote on executive compensation philosophy and policies was approved with a 66-2/3% majority requirement met.
- More than 50% of issued share capital was represented at the meeting.
Core Laboratories Inc. announced its first quarter 2025 financial results and declared a quarterly cash dividend of $0.01 per share.
📋 Key Facts
- Announced Q1 2025 financial results on April 23, 2025.
- Declared a quarterly cash dividend of $0.01 per share of common stock.
- Record date for the dividend is May 5, 2025.
- Payment date for the dividend is May 27, 2025.
Core Laboratories Inc. announced its financial results for the fourth quarter and full year of 2024, alongside a quarterly cash dividend declaration.
📋 Key Facts
- Announced Q4 and FY 2024 financial results on January 29, 2025.
- Declared a quarterly cash dividend of $0.01 per share of common stock.
- Record date for the dividend is February 10, 2025.
- Payment date for the dividend is March 3, 2025.
Core Laboratories Inc. announced its third quarter 2024 financial results and declared a quarterly cash dividend of $0.01 per share.
📋 Key Facts
- Announced Q3 2024 financial results on October 23, 2024 (Item 2.02).
- Declared a quarterly cash dividend of $0.01 per share of common stock (Item 7.01).
- Record date for the dividend is November 4, 2024.
- Payment date for the dividend is November 25, 2024.
Core Laboratories Inc. announced its second quarter 2024 financial results and declared a quarterly cash dividend of $0.01 per share.
📋 Key Facts
- Announced Q2 2024 financial results on July 24, 2024.
- Declared a quarterly cash dividend of $0.01 per share of common stock.
- Record date for the dividend is August 5, 2024.
- Payment date for the dividend is August 26, 2024.
Core Laboratories Inc. held its Annual Meeting of Shareholders on May 8, 2024, where shareholders approved all presented proposals. The results included the election of Class III directors and the ratification of KPMG LLP as independent auditors.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on May 8, 2024, in Houston, Texas.
- Proposal 1: Election of Lawrence Bruno and Kwaku Temeng to Class III Directors was approved.
- Proposal 2: Ratification of KPMG LLP as independent registered public accountants for the fiscal year ending Dec 31, 2024, was approved with 40,402,356 votes 'For'.
- Proposal 3: Advisory vote on executive compensation philosophy and policies was approved.
- Proposal 4: Amendment and restatement of the 2020 Long-Term Incentive Plan (increasing authorized shares and extending term to May 8, 2034) was approved by a two-thirds majority.
Core Laboratories Inc. announced its first quarter 2024 financial results and declared a quarterly cash dividend of $0.01 per share.
📋 Key Facts
- Announced Q1 2024 financial results on April 24, 2024.
- Declared a quarterly cash dividend of $0.01 per share of common stock.
- Record date for the dividend is May 6, 2024.
- Payment date for the dividend is May 28, 2024.
Core Laboratories Inc. announced the resignation of its Vice President and Chief Accounting Officer, Kevin Daniels, effective March 21, 2024. The company has appointed Sow Hang Teo, previously the Corporate Controller of Financial Reporting, to succeed him.
🚩 Red Flags
- None identified; departure is characterized as non-dispute related.
📋 Key Facts
- Kevin Daniels resigned as VP and Chief Accounting Officer on March 21, 2024, to pursue other opportunities.
- The departure is explicitly stated not to be due to any dispute or disagreement regarding accounting practices or financial statements.
- Sow Hang Teo appointed as new VP and Chief Accounting Officer effective March 21, 2024.
- Mr. Teo has been with the company since February 2006 and was previously the Corporate Controller of Financial Reporting.
Core Laboratories Inc. filed an amended 8-K to correct unaudited financial information for the quarter and year ended December 31, 2023. The correction stems from a $4.3 million understatement of estimated income tax expense due to a reassessment of foreign tax credits following the company's redomestication from the Netherlands to the United States.
🚩 Red Flags
- Restatement of previously issued unaudited quarterly results (8-K/A).
- Significant change in effective tax rate due to redomestication complexities.
- Revision of key performance metric (ROIC) following the error.
📋 Key Facts
- Corrected unaudited income tax expense for Q4 2023, which was understated by $4.3 million.
- Revised Net Income for the full year 2023 from $41,289k to $37,025k.
- Revised Diluted EPS for the full year 2023 from $0.86 to $0.77.
- The adjustment resulted in a revision of Return on Invested Capital (ROIC) for Q4 2023 from 13.4% to 12.0%.
- The error was identified during the preparation of audited financial statements for the Form 10-K.
- The adjustment did not impact consolidated revenue, operating income, or cash from operations.
Core Laboratories Inc. issued an 8-K to announce its fourth quarter and full year 2023 financial results and a quarterly cash dividend declaration.
📋 Key Facts
- Announced Q4 and FY 2023 financial results on January 31, 2024.
- Declared a quarterly cash dividend of $0.01 per share of common stock.
- Dividend record date: February 12, 2024; Payment date: March 4, 2024.